EcoDrugPlus

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDCDG00000005437
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDCDG00000029412
Gene Symbol: ADAM17
1 Cross references
209 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSDCDG00000029492
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSDCDG00000002888
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSDCDG00000022593
Gene Symbol: AKT1
3 Cross references
193 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSDCDG00000000397
Gene Symbol: AKT1
3 Cross references
139 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSDCDG00000000142
Gene Symbol: ALK
3 Cross references
195 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSDCDG00000019317
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSDCDG00000026610
Gene Symbol: ABCC8
3 Cross references
168 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSDCDG00000007647
Gene Symbol: ABCC8
3 Cross references
230 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSDCDG00000023067
Gene Symbol: ABCC8
3 Cross references
168 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 9

Ensembl ID : ENSDCDG00000035428
Gene Symbol: ABCC9
3 Cross references
233 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).